Cancer Genomics for Personalized Medicine

Thursday, November 10, 2011
5:30 - 8:00 pm Scottsdale Resort Hilton
6333 North Scottsdale Road, Scottsdale, AZ 85250, 480-948-7750

• At the door, $50
• MIT EF-Phoenix Member, Affiliate, member's family, $40
• Entrepreneur Showcase Exhibitor, $40 (See webpage for Exhibitors for suggestions)
  
• Not affiliated with MIT Enterprise Forum-Phoenix, $45
• 1-year membership to the MIT EF-Phx, incluging 1 ticket, $100

"For the first time, scientists can track the precise genetic changes behind an individual case of cancer. …it could change the way we treat the disease.”

                                                        -- Technology Review, January 2011
The Entrepreneurs’ Showcase starts at 5:30 pm where you can meet startup teams in the diverse medical business, from diagnostics and devices to health care records.

Please enjoy networking, the light buffet and cash bar.

The panel discussion begins with a non-technical overview of the status of cancer genomics and will emphasize the entrepreneurial opportunities for personalized medicine.

Seed the Q&A session with your ideas at our Facebook page, Linkedin group,  Twitter and Meetup sites. Send your comments now. Send this announcement to YOUR contacts.

Speakers

MaryAnn Guerra, MBA, is the Chief Executive Officer and co-founder of BioAccel. Ms. Guerra’s executive positions at the National Institutes of Health were Deputy Director of Management and Executive Officer at the National Cancer Institute; Executive Officer of the National Heart, Lung, and Blood Institute; and Chief of the Technology Transfer and Intramural Management Branch at the National Institute of Allergy and Infectious Diseases.

Ron King, Ph.D., MBA, is the Chief Science and Business Officer and a co-founder of BioAccel. Dr. King is expert in integrating science and business by creating innovative programs to transform new technologies into products and business opportunities. Dr. King helped manage the development of several technology programs associated with the Human Genome Project.

John Carpten, PhD, is Translational Genomics Research Institute’s (Tgen) director of Integrated Cancer Genomics. He discovered mutations in the genes responsible for prostate cancer, congenital joint diseases and hyperparathyroidism jaw-tumor syndrome. He has begun to apply Next Generation Sequencing technologies to profiling tumors.

Pat Elliott is an e-Patient Advocate whose blood cancer is treated with targeted gene therapy. Her career included entrepreneurship and executive roles at HP, Intel and Motorola Healthcare. Today, she works with the health media companies PatientPower and EmpowHER, and supports cancer patients through blogging, hosting programs on patient portals, building global online patient communities and more.  

Our Sponsors Include: